Cerus Endovascular

14 articles about Cerus Endovascular

• Cerus Endovascular Names Stephen Griffin as Chief Executive Officer

  7/12/2022

  Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today the appointment of Stephen Griffin , Ph.D. to Chief Executive Officer, effective immediately.

• Cerus Endovascular Receives U.S. Food and Drug Administration 510(k) Clearance of its 027 Micro-catheter

  3/23/2022

  Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 027 micro-catheters, available in two lengths, expanding its product portfolio which includes the already FDA cleared 021 micro-catheter platform.

• Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

  4/21/2021

  Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms.

• Cerus Endovascular and Balt Enter Strategic Distribution Agreement for Innovative Neurovascular Devices to Treat a Range of Intracranial Aneurysms

  8/4/2020

  Balt to Commercialize Cerus Endovascular's Contour Neurovascular System™ and Neqstent Coil Assisted Flow Diverter in Germany

• Cerus Endovascular Receives CE Mark Approval for its CerusEndo MC 021 Microcatheter

  7/28/2020

  Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020

• Cerus Endovascular Receives CE Mark Approval for its 021 Contour Neurovascular System™

  4/29/2020

  Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, announced that it has received CE Mark approval for its 021 Contour Neurovascular System™, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms.

• Cerus Endovascular Receives CE Mark Approvals for its Neqstent™ Coil Assisted Flow Diverter Designed to Treat Intracranial Aneurysms

  4/22/2020

  Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020

• Cerus Endovascular Successfully Completes Series B Financing and Receives U.S. FDA Approval for its First Microcatheter

  2/21/2020

  Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has now successfully completed its Series B financing having raised a total of $19.0 million from current and new institutional investors since commencement of the round in July 2018.

• Cerus Endovascular Receives CE Mark Approval for its Contour Neurovascular System™, Designed to Treat Intracranial Aneurysms

  2/18/2020

  Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its lead product, the Contour Neurovascular System™, for the treatment of intracranial aneurysms.

• Cerus Endovascular Expands Intellectual Property Portfolio

  11/27/2018

  Brings Patent Portfolio to Five Issued U.S. Patents and over 20+ Pending Patent Applications -

• Cerus Endovascular Enrolls First Patients in CERUS Study to Treat Intra-Cranial Aneurysms Using Contour Neurovascular System™ to Reduce the Risk of Rupture

  11/13/2018

  Cerus Endovascular Ltd., a privately held medical device company engaged in developing interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysms, today announced enrollment of the first patients in the CERUS Study (Contour Neurovascular System European Pre-Market Unruptured Aneurysm Study).

• Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne

  9/18/2018

  Mr. Kilcoyne brings more than 30 years of experience in the medical device market to the Cerus Endovascular Board.

• Cerus Endovascular Promotes Stephen Griffin, PhD, to President

  5/11/2018

  Company On-Track to Achieve Key Clinical and Regulatory Milestones

• Cerus Endovascular Provides Corporate Update

  9/8/2017